| EMA number | EMEA/H/C/002513 |
| ATC code | L03AX17 |
| Authorisation | 6 September 2013 |
| Withdrawn | 6 May 2015 |
| Revision | 1 |
Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate-resistant prostate cancer in male adults in whom chemotherapy is not yet clinically indicated.